STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

LXEO insider sale filing: 542 shares post-vesting to be sold on NASDAQ

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Form 144 filed for Lexeo Therapeutics, Inc. (LXEO) reports a proposed sale of 542 common shares, with an aggregate market value of $2,530.16, to be sold on 08/18/2025 on NASDAQ through Fidelity Brokerage Services LLC.

The shares were acquired on 08/15/2025 through restricted stock vesting from the issuer and payment/settlement is recorded as 08/15/2025. The filing shows 54,001,214 shares outstanding for the class and indicates no other sales in the past three months.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Routine Form 144 reporting a small post-vesting sale, immaterial to company capitalization.

The filing documents a proposed sale of 542 shares valued at $2,530.16, executed through a broker on NASDAQ after restricted stock vested three days earlier. Given the class outstanding count of 54,001,214 shares, the size of the sale is negligible relative to total capitalization and is a standard disclosure required under Rule 144. There are no reported sales in the prior three months, and no additional material details about insider intent or plan are provided.

TL;DR: Compliance-focused disclosure of insider sale following restricted stock vesting; no governance red flags apparent.

The notice affirms the signer represents no undisclosed material adverse information and references potential Rule 10b5-1 plan considerations, but does not indicate a trading plan or unusual timing. The transaction appears to be standard post-vesting liquidity by an insider or related person, with routine broker engagement and no past three-month sales reported.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the LXEO Form 144 disclose about the proposed sale?

The filing discloses a proposed sale of 542 common shares valued at $2,530.16, to be sold on 08/18/2025 on NASDAQ via Fidelity Brokerage Services LLC.

How and when were the shares acquired according to the filing?

The shares were acquired on 08/15/2025 through restricted stock vesting from the issuer, with payment/settlement dated 08/15/2025.

How many LXEO shares are outstanding as shown in the Form 144?

The filing reports 54,001,214 shares outstanding for the class of common stock.

Does the Form 144 report any other sales in the past three months for the seller?

No. The filing states "Nothing to Report" for securities sold during the past three months by the person for whose account the shares are to be sold.

Which broker is handling the proposed sale in the filing?

The broker named is Fidelity Brokerage Services LLC located at 900 Salem Street, Smithfield RI 02917.
Lexeo Therapeutics Inc

NASDAQ:LXEO

LXEO Rankings

LXEO Latest News

LXEO Latest SEC Filings

LXEO Stock Data

607.25M
68.04M
0.53%
89.37%
9.69%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
NEW YORK